Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

TIMOLOL FOR SYSTEM SUITABILITY CRS (5.03 MG)

TIMOLOL FOR SYSTEM SUITABILITY CRS (5.03 MG)

26921-17-5

DISCOVER
Aciclovir for peak identification 1 CRS, 0.3mg

Aciclovir for peak identification 1 CRS, 0.3mg

59277-89-3

DISCOVER
ZIPRASIDONE FOR SYSTEM SUITABILITY 1 CRS (10 MG)

ZIPRASIDONE FOR SYSTEM SUITABILITY 1 CRS (10 MG)

138982-67-9

DISCOVER
BAICALIN CRS (20 MG)

BAICALIN CRS (20 MG)

21967-41-9

DISCOVER
FLECAINIDE FOR SYSTEM SUITABILITY CRS (10 MG)

FLECAINIDE FOR SYSTEM SUITABILITY CRS (10 MG)

54143-56-5

DISCOVER
POTASSIUM SUCROSE OCTASULFATECRS (100 MG)

POTASSIUM SUCROSE OCTASULFATECRS (100 MG)

73264-44-5

DISCOVER
RISPERIDONE IMPURITY K CRS (0.015 MG)

RISPERIDONE IMPURITY K CRS (0.015 MG)

NA

DISCOVER
HYDROXYETHYL STARCH (MEDIUM MW) CRS (1200 MG)

HYDROXYETHYL STARCH (MEDIUM MW) CRS (1200 MG)

9005-27-0

DISCOVER
NIZATIDINE FOR SYSTEM SUITABILITY CRS (10 MG)

NIZATIDINE FOR SYSTEM SUITABILITY CRS (10 MG)

76963-41-2

DISCOVER
GALANTAMINE HYDROBROMIDE CRS (10 MG)

GALANTAMINE HYDROBROMIDE CRS (10 MG)

04/04/1953

DISCOVER
GABAPENTIN CRS (400 MG)

GABAPENTIN CRS (400 MG)

60142-96-3

DISCOVER
GABAPENTIN IMPURITY A CRS (20MG)

GABAPENTIN IMPURITY A CRS (20MG)

64744-50-9

DISCOVER